Knowledge mapping of targeted therapy for hypertrophic cardiomyopathy: A bibliometric analysis of myosin inhibitor research

作者：Liu N, Yang L, Tian W, Song X, Fu H, Zhang H, Wang J, Zhu Z, Qu Z, Shang Q · 发表于：Medicine · 年份：2026 · DOI：10.1097/md.0000000000050034 · 被引用次数：39 · 研究领域：bibliometric analysis、hypertrophic cardiomyopathy、mavacamten、myosin inhibitor、targeted therapy

BACKGROUND: Targeted therapy using myosin inhibitors represents a groundbreaking advancement in the management of hypertrophic cardiomyopathy (HCM). This study conducts a comprehensive bibliometric analysis to map the research landscape indexed in the Web of Science Core Collection, identify key trends, and evaluate the scientific impact of myosin inhibitor studies from 2016 to 2025. METHODS: We systematically retrieved publications from the Web of Science Core Collection using predefined search terms related to myosin inhibitors and HCM. Utilizing VOSviewer software, CiteSpace, and R-Bibliometrix Package, we performed co-authorship, co-citation, and keyword co-occurrence analyses. Bibliometric indicators (e.g., publication volume, citations, h-index) were employed to assess research productivity and influence. RESULTS: This bibliometric analysis encompassed 379 publications (2016-2025) on myosin inhibitors for HCM, showing exponential growth. The United States dominated research output (37% of total publications), followed by Italy (30 publications) and Germany (14 publications). Leading institutions included the University of Pennsylvania (39 publications, 1585 citations) and Bristol Myers Squibb (32 publications). Journal of the American College of Cardiology emerged as the top publishing venue (16 papers, 937 citations). Key researchers were identified: Olivotto I (most productive, 40 papers, h-index = 16), Saberi S (most cited, 1957 citations), and Sehnert AJ (highest ...